Navigation Links
Prometic provides information for its Annual and Special Meeting of Shareholders
Date:5/1/2008

placing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.


'/>"/>
SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
2. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
3. Prometic to present at the American Chemical Society
4. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
7. ProMetic provides business update - Over $35 million worth of business secured in January
8. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
9. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
10. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
11. Genzyme Provides Update on Myozyme(R) Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 ... State-of-the-art facility and complementary therapies brings comprehensive cancer ... foot, state-of-the-art Yuma Regional Cancer Center has officially ... 2012, the program includes services such as open, ... massage therapy, American Cancer Society Resource Center, hematology, ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a private ... personalize and advance the treatment and management of cancer, ... as chairman of Epic,s board of directors. Mr. ... (formerly Invitrogen). Mr. Lucier joins Epic,s board of directors ... cell analysis platform with special focus on the development ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... announces that a new market research report is ... Oxide: 2010 World Market Outlook And Forecast ... report analyzes worldwide markets for Propylene oxide, including ... provides the most complete and current analytical account ...
... (Nasdaq: MYL ) today announced its financial results for ... its financial guidance for 2011.   Financial Results ... ended December 31, 2010 compared to $0.33 for the same prior ... of $1.61 for the year ended December 31, 2010 compared to ...
... in German . , They have been used ... now they are making rapid inroads in high performance applications: ... phones and digital cameras. The automotive industry, for instance, has ... using them in driver assistance systems from parking aids ...
Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 16Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 17Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 18UV-transparent coating for image sensors 2
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2F1000Research brings static research figures to life 2
... studies reveal that voting decisions are more associated ... a politician,s appearance than to positive ones, says ... of Technology (Caltech), Scripps College, Princeton University, and ... particularly true when voters have little or no ...
... beware. Chances are your male partner is on your ... even when you have kept to the straight and ... constant vigilance, women may be better than men at ... in Richmond and colleagues gave 203 young heterosexual couples ...
... sustainability expert Deane Evans will provide an introduction to the basics of ... seminar, open to the public, at NJIT. The talk, set ... a review of the status of the NJ schools, construction program. ... Evans, a registered architect, is executive director ...
Cached Biology News:Caltech-led researchers find negative cues from appearance alone matter for real elections 2Caltech-led researchers find negative cues from appearance alone matter for real elections 3Caltech-led researchers find negative cues from appearance alone matter for real elections 4Men are better at detecting infidelities 2
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... precision beveling of micropipette tips ... unique abrasive plate drive system ... control of the beveling process. ... rapidly and produces consistent tip ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: